Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation

Transplant Immunology

Volumn 26, Issue 4, 2012, Pages 235-239

  Wang, Dong ^a   Wu, Guojun ^b   Chen, Jinhua ^a   Yu, Ziqiang ^a   Wu, Weizhen ^a   Yang, Shunliang ^a   Tan, Jianming ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Graft loss; HLA antibodies; Renal transplantation; Soluble CD30

Indexed keywords

CD30 ANTIGEN; HLA ANTIBODY;

ADULT; ARTICLE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; ANTIBODIES; ANTIGENS, CD30; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84860432956     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.03.002     Document Type: Article

References (27)

1. Morris P.J., Williams G.M., Hume D.M., et al. Serotyping for homotransplantation. XII. Occurrence of cytotoxic antibodies following kidney transplantation in man. Transplantation 1968, 6:392-399.
2. Bartel G., Regele H., Wahrmann M., et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008 Dec, 8(12):2652-2660.
3. Bohmig G.A., Bartel G., Regele H., Wahrmann M. Prospects and limitations of posttransplantation alloantibody detection in renal transplantation. Hum Immunol 2009, 70:640-644.
4. Worthington J.E., Martin S., Al-Husseini D.M., et al. Post-transplant production of donor HLA specific antibodies as a predictor of renal transplant outcome. Transplantation 2003, 75:1034-1040.
5. Lachmann N., Terasaki P.I., Budde K., et al. Antihuman leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009, 87:1505-1513.
6. Einecke G., Sis B., Reeve J., et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009, 9:2520-2531.
7. Pelzl S., Opelz G., Wiesel M., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002, 73(1):3-6.
8. Susal C., Pelzl S., Dohler B., et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13(6):1650-1656.
9. Pelzl S., Opelz G., Daniel V., et al. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75(3):421-423.
10. Rajakariar R., Jivanji N., Varagunam M., et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 2005, 5(8):1922-1925.
11. Wang D., Yang S.L., Wu W.Z., et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 2006, 16(1):41-45.
12. Wang D., Wu W.Z., Chen J.H., et al. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal tran splant recipients. Transpl Immunol 2010, 22(3-4):115-120.
13. Wang D., Wu G.J., Wu W.Z., et al. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol 2007, 17(4):278-282.
14. Terasaki P.I., Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004, 4(3):438-443.
15. Mao Q., Terasaki P.I., Cai J., et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007, 7(4):864-871.
16. Lefaucheur C., Suberbielle-Boissel C., Hill G.S., et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008, 8(2):324-331.
17. Alvarez-Márquez A., Aguilera I., Gentil M.A., et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 2009, 87(1):94-99.
18. Hidalgo L.G., Campbell P.M., Sis B., et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009, 9(11):2532-2541.
19. Weimer R., Süsal C., Yildiz S., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006, 6(8):1865-1874.
20. Langan L.L., Park L.P., Hughes T.L., et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007, 7(4):847-856.
21. Pelletier R.P., Hennessy P.K., Adams P.W., et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002, 2(2):134-141.
22. Issa N., Cosio F.G., Gloor J.M., et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008, 86(5):681-685.
23. Lee P.C., Zhu L., Terasaki P.I., et al. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009, 88(4):568-574.
24. Everly M.J., Everly J.J., Arend L.J., et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009, 9(5):1063-1071.
25. Everly M.J., Everly J.J., Susskind B., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86(12):1754-1761.
26. Süsal C., Döhler B., Sadeghi M., et al. Posttransplant sCD30 as a Predictor of Kidney Graft Outcome. Transplantation 2011, 91(12):1364-1369.
27. Martinez O.M., Villanueva J., Abtahi S., et al. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998, 65(9):1240-1247.